Item 9B. OTHER INFORMATION

Trading Plans

During the three months ended December 31, 2023, the following Section 16 officers and directors adopted or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act):


Name	Title	Action	Action Date	Aggregate Number of Shares to be Sold(1)	Expiration Date(2)
Matthew Dolan	Executive Vice President, Strategy, Corporate Development and Dexcom Labs	Adoption	12/15/2023	15,326	12/15/2024
Paul Flynn	Executive Vice President, Global Revenue	Adoption	12/15/2023	31,253	12/15/2024
Girish Naganathan	Executive Vice President, Chief Technology Officer	Adoption	11/20/2023	5,137	11/20/2024

Steven R. Pacelli	Executive Vice President and Managing Director, Dexcom Ventures	Adoption	11/27/2023	15,000	1/23/2025
Barry J. Regan	Executive Vice President, Global Operations	Adoption	12/4/2023	28,430	12/4/2024
Kevin R. Sayer	Chairperson, President and Chief Executive Officer	Adoption	12/12/2023	100,965	12/12/2024
Sadie M. Stern	Executive Vice President, Chief Human Resources Officer	Adoption(3)	12/12/2023	12,825	3/11/2025
Sadie M. Stern	Executive Vice President, Chief Human Resources Officer	Termination(3)	12/12/2023	4,708	3/8/2024
Jereme M. Sylvain	Executive Vice President, Chief Financial Officer	Adoption	11/21/2023	6,863	11/21/2024


(1) The actual number of shares sold may depend on the net shares vested as a result of tax withholding obligations, the vesting of certain performance-based stock units, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time.
(2) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the date listed in the table.
(3) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 12, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act.

Each of the Rule 10b5-1 trading arrangements that were adopted in the above table are in accordance with our insider trading policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.

No Section 16 officers or directors adopted, modified, or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) during the three months ended December 31, 2023.

Previous: Item 9A. CONTROLS AND PROCEDURES · Next: Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS